Lower injection‐site reactions and long‐term safety, immunogenicity, and efficacy of etanercept biosimilar YLB113 : Results from a post‐hoc analysis of a double‐blind, randomized, phase III comparative study and its open‐label extension in patients with rheumatoid arthritis

Hisashi Yamanaka,Yoshiya Tanaka,Toshihiko Hibino,Gopalakrishnan Unmesh,Chirag Shah,Dhananjay Bakhle,Dimitris Stefanidis

International Journal of Rheumatic Diseases（2022）

引用 1|浏览4

暂无评分

摘要

YLB113 demonstrated long-term safety and sustained efficacy for up to 96 weeks. Patients on YLB113 experienced significantly lower ISRs and ISE in a post-hoc analysis of the phase III study when compared with reference product.

查看译文

关键词

YLB113,biosimilar,etanercept,injection-site reaction,long-term safety,rheumatoid arthritis

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要